Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica

Journal of Neuroimmunology

Volumn 282, Issue , 2015, Pages 92-96

  Viswanathan, Shanthi ^a   Wong, Anna H Y ^b   Quek, Amy M L ^b   Yuki, Nobuhiro ^b,c  

^a HOSPITAL KUALA LUMPUR   (Malaysia)

^b Dept Medicine Endocrinol Diabet   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Intravenous immunoglobulin; Neuromyelitis optica; Neuromyelitis optica spectrum disorder; Relapse rate

Indexed keywords

AQUAPORIN 4 ANTIBODY; AZATHIOPRINE; IMMUNOGLOBULIN; PREDNISOLONE; AQP4 PROTEIN, HUMAN; AQUAPORIN 4; IMMUNOLOGIC FACTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; DETERIORATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; INFUSION RELATED REACTION; MAINTENANCE THERAPY; MYELITIS; MYELOOPTIC NEUROPATHY; OPTIC NEURITIS; PRIORITY JOURNAL; PRURITUS; RECURRENCE RISK; REMISSION; RETROSPECTIVE STUDY; TREATMENT DURATION; URTICARIA; YOUNG ADULT; DISABILITY; FOLLOW UP; IMMUNOLOGY; MALE; NEUROMYELITIS OPTICA; RECURRENT DISEASE; SEVERITY OF ILLNESS INDEX;

ADULT; AQUAPORIN 4; DISABILITY EVALUATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MALE; NEUROMYELITIS OPTICA; RECURRENCE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84928567337     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2015.03.021     Document Type: Article

References (29)

1. Bakker J., Metz L. Devic's neuromyelitis optica treated with intravenous gamma globulin (IVIG). Can. J. Neurol. Sci. 2004, 31:265-267.
2. Ballow M. Safety of IVIG therapy and infusion-related adverse events. Immunol. Res. 2007, 38:122-132.
3. Bennett J.L., Lam C., Kalluri S.R., Saikali P., Bautista K., Dupree C., Glogowska M., Case D., Antel J.P., Owens G.P., Gilden D., Nessler S., Stadelmann C., Hemmer B. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann. Neurol. 2009, 66:617-629.
4. Bichuetti D., Boulos F., Shinosaki J., Souza N., Oliveira E., Gabbai A. Treatment of neuromyelitis optica with intravenous immunoglobulin: report of 8 patients. Neurology 2012, 78:P04.141.
5. Bichuetti-Silva D.C., Furlan F.P., Nobre F.A., Pereira C.T., Goncalves T.R., Gouveia-Pereira M., Rota R., Tavares L., Mazzucchelli J.T., Costa-Carvalho B.T. Immediate infusion-related adverse reactions to intravenous immunoglobulin in a prospective cohort of 1765 infusions. Int. Immunopharmacol. 2014, 23:442-446.
6. Bradl M., Lassmann D.H. Anti-aquaporin-4 antibodies in neuromyelitis optica: how to prove their pathogenetic relevance?. Int. MS J. 2008, 15:75-78.
7. Elsone L., Mutch K., Jacob A. IVIG in NMO Refractory/Intolerant to Rituximab 2014, 85. e4. (doi:10.1136).
8. Elsone L., Panicker J., Mutch K., Boggild M., Appleton R., Jacob A. Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients. Mult. Scler. 2014, 20:501-504.
9. Gelfand E.W. Intravenous immune globulin in autoimmune and inflammatory diseases. N. Engl. J. Med. 2012, 367:2015-2025.
10. Jacob S., Rajabally Y.A. Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies. Curr. Neuropharmacol. 2009, 7:337-342.
11. Jacob A., Weinshenker B.G., Violich I., McLinskey N., Krupp L., Fox R.J., Wingerchuk D.M., Boggild M., Constantinescu C.S., Miller A., De Angelis T., Matiello M., Cree B.A. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch. Neurol. 2008, 65:1443-1448.
12. Kim W., Kim S.H., Kim H.J. New insights into neuromyelitis optica. J. Clin. Neurol. 2011, 7:115-127.
13. Kim S.H., Kim W., Li X.F., Jung I.J., Kim H.J. Does interferon beta treatment exacerbate neuromyelitis optica. Mult. Scler. 2012, 18:1480-1483.
14. Kimbrough D.J., Fujihara K., Jacob A., Lana-Peixoto M.A., Leite M.I., Levy M., Marignier R., Nakashima I., Palace J., de Seze J., Stuve O., Tenembaum S.N., Traboulsee A., Waubant E., Weinshenker B.G., Wingerchuk D.M. Treatment of neuromyelitis optica: review and recommendations. Mult. Scler. Relat. Disord. 2012, 1:180-187.
15. Kleiter I., Hellwig K., Berthele A., Kümpfel T., Linker R.A., Hartung H.P., Paul F., Aktas O., Neuromyelitis Optica Study Group Failure of natazulimab to prevent relapses in neuromyelitis optica. Arch. Neurol. 2012, 69:239-245.
16. Li Y., Shindo A., Sasuki R., Naito Y., Tanaka K., Kuzuhara S. Reversible stenosis of large cerebral arteries in a patient with combined Sjögren's syndrome and neuromyelitis optica spectrum disorder. Rheumatol. Int. 2008, 28:1277-1280.
17. Lin C.Y., Wang K.C., Hsu L.C., Lin K.H., Tsai C.P. Early intravenous immunoglobulin (IVIG) may be effective in severe brainstem-spinal encephalo-myelopathy refractory to steroid suggestive of neuromyelitis optica spectrum disorder. Neurol. Asia 2012, 17:159-162.
18. Magraner M.J., Coret F., Casanova B. The effect of intravenous immunoglobulin on neuromyelitis optica. Neurologia 2013, 28:65-72.
19. Min J.H., Kim B.J., Lee K.H. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult. Scler. 2012, 18:113-115.
20. Okada K., Tsuji S., Tanaka K. Intermittent intravenous immunoglobulin successfully prevents relapses of neuromyelitis optica. Int. Med. 2007, 46:1671-1672.
21. Ratelade J., Smith A.J., Verkman A.S. Human immunoglobulin G reduces pathogenicity of aquaporin-4 autoantibodies in neuromyelitis optica. Exp. Neurol. 2014, 255:145-153.
22. Saadoun S., Waters P., Bell B.A., Vincent A., Verkman A.S., Papadopoulos M.C. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 2010, 133:349-361.
23. Sato D., Callegaro D., Lana-Peixoto M.A., Fujihara K. Treatment of neuromyelitis optica: an evidence based review. Arq. Neuropsiquiatr. 2012, 70:59-66.
24. Sellner J., Boggild M., Clanet M., Hintzen R.Q., IIes Z., Montalban X., Du Pasquier R.A., Polman C.H., Sorensen P.S., Hemmer B. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur. J. Neurol. 2010, 17:1019-1032.
25. Tan C.T. Multiple sclerosis in Malaysia. Arch. Neurol. 1988, 45:624-627.
26. Tan C.T. Multiple sclerosis in Malaysia. Neurol. J. Southeast. Asia 1997, 2:1-5.
27. Trebst C., Jarius S., Berthele A., Friedemann P., Schippling S., Wildemann B., Borisow N., Kleiter I., Aktas O., Kumpfel T., Neuromyelitis Optica Study Group (NEMOS) Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J. Neurol. 2014, 261:1-16.
28. Wingerchuk D.M., Lennon V.A., Pittock S.J., Lucchinetti C.F., Weinshenker B.G. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006, 66:1485-1489.
29. Wingerchuk D.M., Lennon V.A., Luchinetti C.F., Pittock S.J., Weinshenker B.G. The spectrum of neuromyelitis optica. Lancet Neurol. 2007, 6:805-815.